HK inno.N Corporation (KOSDAQ:195940)

South Korea flag South Korea · Delayed Price · Currency is KRW
48,650
-450 (-0.92%)
Aug 28, 2025, 3:30 PM KST
-0.92%
Market Cap1.38T
Revenue (ttm)839.63B
Net Income (ttm)41.49B
Shares Out28.33M
EPS (ttm)1,451.65
PE Ratio33.51
Forward PE16.40
Dividend350.00 (0.71%)
Ex-Dividend DateMar 28, 2025
Volume151,467
Average Volume376,539
Open49,100
Previous Close49,100
Day's Range48,550 - 49,600
52-Week Range31,650 - 53,100
Beta0.69
RSI67.63
Earnings DateOct 30, 2025

About HK inno.N

HK inno.N Corporation engages in the pharmaceutical business in South Korea. The company offers prescription drugs for the treatment of gram-positive and gram-negative organisms, enterococcus faecium infections, vancomycin-resistant, acute bacterial sinusitis, bronchitis, neumonia, antibiotics, and infections caused by microorganism; anemia and hemodialysis; diabetes; hypertension, primary hypercholesterinemia, homozygous familial hypercholesterolemia, and hypertension with dyslipidemia; GERD, EE, NERD, GU and H.Pylori; pleural mesothelioma, no... [Read more]

Industry Pharmaceutical Preparations
Founded 1984
Employees 1,695
Stock Exchange KOSDAQ
Ticker Symbol 195940
Full Company Profile

Financial Performance

In 2021, HK inno.N's revenue was 769.79 billion, an increase of 28.63% compared to the previous year's 598.45 billion. Earnings were 21.35 billion, a decrease of -23.49%.

Financial Statements

News

There is no news available yet.